Evidence map›Paper›PMID 26925970›Full record

ArticlePLoS genetics2016

A Parent-of-Origin Effect Impacts the Phenotype in Low Penetrance Retinoblastoma Families Segregating the c.1981C>T/p.Arg661Trp Mutation of RB1.

Philippine Eloy, Catherine Dehainault, Meriem Sefta, Isabelle Aerts, François Doz, Nathalie Cassoux, Livia Lumbroso le Rouic, Dominique Stoppa-Lyonnet, François Radvanyi, Gaël A Millot and 2 more

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Decrease ofFrontiers in medicine · 2022
    Article
  9. Parental Origin of theCancers · 2021
    Article
  10. Article
  11. Article
  12. Article
  13. Frontiers in oncology · 2020
    Article
  14. Article
  15. Article
  16. Article
  17. Heterogeneity in retinoblastoma: a tale of molecules and models.Clinical and translational medicine · 2017
    Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Philippine EloyService de Génétique, Institut Curie, Paris, France.
Catherine DehainaultService de Génétique, Institut Curie, Paris, France.
Meriem SeftaCNRS UMR144, centre de recherche de l'Institut Curie, Paris, France.
Isabelle AertsDépartement d'oncologie pédiatrique, adolescents jeunes adultes, Institut Curie, Paris, France.
François DozDépartement d'oncologie pédiatrique, adolescents jeunes adultes, Institut Curie, Paris, France.
Nathalie CassouxUniversité Paris Descartes, Sorbonne Paris Cité, Paris, France.
Livia Lumbroso le RouicDépartement d'oncologie chirurgicale, service d'Ophtalmologie, Institut Curie, Paris, France.
Dominique Stoppa-LyonnetService de Génétique, Institut Curie, Paris, France.
François RadvanyiCNRS UMR144, centre de recherche de l'Institut Curie, Paris, France.
Gaël A MillotInstitut Curie, PSL Research University, Paris, France.
Marion Gauthier-VillarsService de Génétique, Institut Curie, Paris, France.
Claude HoudayerService de Génétique, Institut Curie, Paris, France.
Délégation Paris 5 · FRInstitut Curie · FRCentre National de la Recherche Scientifique · FRInstitut d’Hématologie et d’Oncologie Pédiatrique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Retinoblastoma (Rb), the most common pediatric intraocular neoplasm, results from inactivation of both alleles of the RB1 tumor suppressor gene. The second allele is most commonly lost, as demonstrated by loss of heterozygosity studies. RB1 germline carriers usually develop bilateral tumors, but some Rb families display low penetrance and variable expressivity. In order to decipher the underlying mechanisms, 23 unrelated low penetrance pedigrees segregating the common c.1981C>T/p.Arg661Trp mutation and other low penetrance mutations were studied. In families segregating the c.1981C>T mutation, we demonstrated, for the first time, a correlation between the gender of the transmitting carrier and penetrance, as evidenced by Fisher's exact test: the probability of being unaffected is 90.3% and 32.5% when the mutation is inherited from the mother and the father, respectively (p-value = 7.10(-7). Interestingly, a similar correlation was observed in families segregating other low penetrance alleles. Consequently, we investigated the putative involvement of an imprinted, modifier gene in low penetrance Rb. We first ruled out a MED4-driven mechanism by MED4 methylation and expression analyses. We then focused on the differentially methylated CpG85 island located in intron 2 of RB1 and showing parent-of-origin-specific DNA methylation. This differential methylation promotes expression of the maternal c.1981C>T allele. We propose that the maternally inherited c.1981C>T/p.Arg661Trp allele retains sufficient tumor suppressor activity to prevent retinoblastoma development. In contrast, when the mutation is paternally transmitted, the low residual activity would mimic a null mutation and subsequently lead to retinoblastoma. This implies that the c.1981C>T mutation is not deleterious per se but needs to be destabilized in order to reach pRb haploinsufficiency and initiate tumorigenesis. We suggest that this phenomenon might be a general mechanism to explain phenotypic differences in low penetrance Rb families.

Indexed as

MutationCpG IslandsDNA MethylationFemaleHeterozygoteHumansMaleMediator ComplexPedigreePenetrancePhenotypeRetinal NeoplasmsRetinoblastomaRetinoblastoma ProteinMED4 protein, humanMediator ComplexRetinoblastoma Protein

Identifiers

PMID26925970
PMCPMC4771840
OpenAlexW2288914183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.